Agomab director reports stock option holdings

Agomab Therapeutics director Angelika Martha Jahreis reported her existing stock option holdings in a Form 3.

Rhea-AI Filing Summary

Agomab Therapeutics director Angelika Martha Jahreis reported her existing stock option holdings in a Form 3. She holds several options over common shares, including 94,438 shares at an exercise price of $3.10 per share expiring on October 10, 2033. Other options cover 1,884, 27,165 and 31,505 underlying shares with exercise prices from $2.81 to $14.26 and expirations between July 8, 2034 and January 15, 2036. Footnotes state some options are fully vested, while others vest in scheduled monthly installments from February 9, 2026 and February 9, 2027, contingent on continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Jahreis Angelika Martha

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 154,992 contracts (Direct)

Footnotes (5)

1. F1. The shares underlying this option are fully vested and exercisable.
2. F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
3. F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
4. F4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
5. F5. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Agomab Therapeutics (AGMB) director Angelika Martha Jahreis report in this Form 3?

She reports her existing holdings of stock options over Agomab common shares. The options give rights to buy multiple share blocks at set prices and expirations, with vesting schedules tied to continued service on specified future dates.

How many Agomab (AGMB) shares are covered by Angelika Martha Jahreis’s largest reported stock option?

Her largest reported stock option covers 94,438 underlying common shares at an exercise price of $3.10 per share. This option is fully vested and exercisable and is scheduled to expire on October 10, 2033, according to the disclosed data.

What are the exercise price ranges of the Agomab (AGMB) stock options reported by Angelika Martha Jahreis?

The reported stock options have exercise prices between $2.81 and $14.26 per share. These prices are shown in U.S. dollars and reflect conversion from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

When do Angelika Martha Jahreis’s Agomab (AGMB) stock options expire?

The options have expiration dates ranging from October 10, 2033 to January 15, 2036. Each grant lists a specific expiration date, after which the right to exercise that option and purchase the underlying Agomab common shares will lapse if unused.

How do the vesting schedules work for the Agomab (AGMB) options reported by Angelika Martha Jahreis?

One option had 50% of its underlying shares vest on February 9, 2026, with the remainder vesting in 24 equal monthly installments. Another option vests 33% on February 9, 2027, with the balance vesting in 24 monthly installments, subject to continued service.

Can Agomab (AGMB) stock options reported by Angelika Martha Jahreis be settled using American Depositary Shares (ADS)?

Yes. The disclosure notes the common shares underlying these stock options may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, providing an alternative way to hold or trade the underlying equity interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jahreis Angelika Martha

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	10/10/2033	Common shares(2)	94,438	$3.1(3)	D
Stock Option (Right to Buy)	(4)	07/08/2034	Common shares(2)	1,884	$2.81(3)	D
Stock Option (Right to Buy)	(4)	11/04/2034	Common shares(2)	27,165	$5.26(3)	D
Stock Option (Right to Buy)	(5)	01/15/2036	Common shares(2)	31,505	$14.26(3)	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

5. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)